Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Latest news

Sign up for updates
    • 13/02/2019
    • News

    Thibaut D’hulst and Darach Connolly quoted by Politico on the recent German Bundeskartellampt decision on Facebook

    Van Bael & Bellis counsel Thibaut D’hulst and associate Darach Connolly were quoted by Politico on the recent Facebook decision by the German competition authority – the Bundeskartellampt – which links data protection and competition law in a novel decision.

    Read more
    • 04/02/2019
    • News

    Van Bael & Bellis promotes Thibaut D’hulst

    Van Bael & Bellis is pleased to announce the promotion of data protection, IT and IP specialist Thibaut D’hulst to Counsel. Thibaut joined Van Bael & Bellis in 2006. He assists clients in ensuring compliance with the EU General Data Protection Regulation (GDPR) and also focuses on intellectual property, pharmaceutical law and competition law. Thibaut commented on his promotion: “My journey at Van Bael & Bellis has been filled with inspirational people and valuable learning experiences. I am grateful to my colleagues and to the partnership for this recognition and look forward to continuing to advance our practice.” Thibaut’s promotion within Van Bael & Bellis is recognition of the firm’s commitment to focus on new areas of growth, whilst maintaining their leading reputation in the areas of competition and international trade. Co-managing partners, Jean-François Bellis and Philippe De Baere commented: Van Bael and Bellis is a client-driven firm which has always brought in the talent necessary to provide the quality services our clients expect. Thibaut has developed a unique expertise in helping our clients structure their businesses in a compliant way that optimises the policy space under the EU’s rules on data protection and intellectual property. Van Bael & Bellis’ Brussels and Geneva offices now include 22 partners, 6 senior counsel, 6 counsel and 34 associates.

    Read more
    • 31/01/2019
    • News

    Andreas Reindl participates in panel session at the Competition Law Nordic conference in Stockholm

    On 30 January 2019, Van Bael & Bellis partner Andreas Reindl participated as a panel member in a session on Vertical Restraints and Distribution: Practical Considerations on the second day of the Competition Law Nordic conference in Stockholm. The other members of the panel were Camilla Robstad (Orkla), Åsa Ericson Hedström (Fiskars Group) and Henrik Okholm (Copenhagen Economics). Further information on the conference is available here.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 14/02/2019
    • Articles

    Overview of the EU’s Single-Use Plastics Directive

    This client alert provides an overview of the EU’s forthcoming “Directive on the reduction of the impact of certain plastic products on the environment”, otherwise known as the single-use plastics Directive. The Directive is expected to enter into force in late spring or early summer 2019 and will have a major impact on the future of the EU plastics market. It is important for both traders and manufacturers to understand how their businesses may be affected as the requirements of the Directive are phased in over the next two to five years.

    Read more
    • 12/02/2019
    • Articles

    European Parliament Raises Issue of Alleged Excessive Pricing of Orphan Medicine

    In a response to two parliamentary questions of 6 February 2019, the member of the European Commission (the “Commission”) responsible for health and food safety Vytenis Andriukaitis announced that the case of chenodeoxycholic acid Leadiant (“CDCA”) will be taken on board in the European Commission’s ongoing assessment of the rules governing orphan medicines. According to the Commissioner, the case is also likely to inform competition investigations of possible excess pricing cases (see attached parliamentary questions and answer). CDCA is indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder. These patients are unable to produce enough of the primary bile acid chenodeoxycholic acid. When primary bile acids are lacking, the body produces abnormal bile acids and other substances instead which accumulate throughout the body, causing damage. Because the number of patients with this condition is very limited, the disease is considered ‘rare’, and CDCA was designated as an orphan medicine in December 2014. CDCA is also a hybrid medicine in that it is similar to a reference medicine, Xenbilox, with the same active substance. However, Xenbilox differs from CDCA in that it is only authorised to dissolve cholesterol gallstones, an indication in use since the 1970s under the name Chenofalk. Leadiant Biosciences (“LB”), the marketing authorisation holder of CDCA, is accused of having monopolised chenodeoxycholic acid and then acquired the exclusive marketing rights associated with the orphan medicine designation of CDCA. The price for the medicine would have gone up considerably. According to one of the Members of Parliament who raised the issue, LB now charges EUR 140 per pill in specific markets, while the medicine cost 30 eurocents per pill when it was still sold as an anti-gallstone medicine. The accusation of excessive pricing is understood to be under review by the Dutch competition authority. The case raises a range of issues and themes that have recently come to the fore in political discussions across the European Union, including the status of orphan medicines; the tackling of excessive prices under the competition rules (the European Commission has not only started a procedure of its own in another file, but says it also supports various efforts of national competition authorities in that area); and possible cooperation among Member States with regard to medicine pricing and reimbursement, a controversial subject which the Commission stresses belongs to the exclusive competencies of the individual Member States.

    Read more
    • 30/01/2019
    • Articles

    Belgium - Liberalisation of distribution channel for medical devices

    A Royal Decree of 18 December 2018 regarding the liberalisation of the distribution channel for medical devices (the “Royal Decree”) was published in the Belgian Official Journal on 28 January 2019. The Royal Decree abolishes a number of provisions for the purpose of allowing supermarkets and other stores to also sell, as from 7 February 2019, certain medical devices that until now could only be sold through pharmacies (these devices are listed in the Royal Decree of 18 March 1999 on medical devices, annex XIII, items 1.1 through 1.5). Belgium thus seeks conformity with Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices pursuant to which “Member States shall not refuse, prohibit or restrict the making available on the market or putting into service within their territory of devices which comply with the requirements of this Regulation” (Article 24). The Royal Decree applies to all medical devices that are available without prescription. In practice, it is expected to impact mainly the distribution of sterile medical devices, such as tubes and band aids, which until now could be sold only through pharmacies. By contrast, the sale of medical devices available on prescription remains limited to pharmacies. The supermarkets and other stores that will sell medical devices under the Royal Decree will have to meet the same quality, security and traceability criteria as the pharmacies and will need to register in advance with the Federal Agency for Medicines and Health Products. According to the Minister of Public Health, Maggie De Block, foreign examples show a marked price decrease of medical devices when these are also made available outside the pharmacy channel. The Minister hopes that the Royal Decree will have the same effect on pricing. Here goes a link to the Dutch and French versions of the Royal Decree of 18 December 2018 : Royal Decree of 18 December 2018

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.